Nara
← Intervention Library

Emerging

Urolithin A

A gut-derived postbiotic studied for mitophagy and muscle function.

Nara’s current positionResearch watchlist
Evidence briefing

Strongest directness: Canine safety / pharmacokinetics. Last reviewed 2026-08-12.

Nara’s evidence view

Research watchlist

PreliminaryCanine safety or pharmacokineticsLow confidence

The claim we’re evaluating

Oral urolithin A meaningfully improves mitochondrial or muscle-related healthy-aging outcomes in dogs.

Nara’s interpretation

Urolithin A is one of the more scientifically credible emerging mitochondrial interventions, but the evidence for meaningful benefit in dogs is not yet direct. Human trials provide preliminary evidence for some muscle-performance and mitochondrial-related effects, while preclinical work strongly supports mitophagy as a mechanism; neither establishes canine healthspan benefit. Nara would therefore treat urolithin A as a research-watchlist intervention rather than as a demonstrated canine healthy-aging intervention.

Personalized

What this means for your dog.

Loading your dog’s context…

Evidence briefing

What Nara knows now.

A bounded position while the full claim-level dossier is still being completed.

What is known

Direct living-dog evidence identified through the cutoff is primarily pharmacokinetic and acute-safety evidence rather than efficacy evidence. A 2026 canine study found improved motility, antioxidant measures and mitochondrial-energy measures when urolithin A was added directly to chilled canine semen, but this was an ex vivo reproductive-biotechnology experiment and does not demonstrate systemic benefit from oral supplementation. Human randomized trials provide stronger translational evidence: urolithin A has altered mitochondrial-related molecular and metabolic markers and improved some muscle-endurance or performance measures, but an important older-adult trial did not significantly improve its primary 6-minute-walk or maximal ATP-production endpoints versus placebo. Preclinical evidence includes mitophagy induction, lifespan extension in C. elegans and muscle-function effects in rodents.

What is not known

No verified randomized canine trial was identified showing that oral urolithin A improves mobility, muscle strength, exercise capacity, cognition, disease incidence, healthspan or lifespan. The 2026 canine sperm study exposed sperm directly to urolithin A ex vivo; it cannot be treated as evidence for oral supplementation in a living dog. Mitophagy is well supported mechanistically in non-canine models, but demonstrating mitophagy does not itself demonstrate a meaningful health outcome. Human efficacy is not uniformly positive: the older-adult randomized trial missed its prespecified primary functional and ATP-production comparisons while showing benefits on secondary endurance and biomarker endpoints. Available canine oral pharmacokinetic/safety evidence is small and does not establish chronic safety or efficacy.

Current position

Urolithin A is one of the more scientifically credible emerging mitochondrial interventions, but the evidence for meaningful benefit in dogs is not yet direct. Human trials provide preliminary evidence for some muscle-performance and mitochondrial-related effects, while preclinical work strongly supports mitophagy as a mechanism; neither establishes canine healthspan benefit. Nara would therefore treat urolithin A as a research-watchlist intervention rather than as a demonstrated canine healthy-aging intervention.

Direct living-dog evidence identified through the cutoff is primarily pharmacokinetic and acute-safety evidence rather than efficacy evidence. A 2026 canine study found improved motility, antioxidant measures and mitochondrial-energy measures when urolithin A was added directly to chilled canine semen, but this was an ex vivo reproductive-biotechnology experiment and does not demonstrate systemic benefit from oral supplementation. Human randomized trials provide stronger translational evidence: urolithin A has altered mitochondrial-related molecular and metabolic markers and improved some muscle-endurance or performance measures, but an important older-adult trial did not significantly improve its primary 6-minute-walk or maximal ATP-production endpoints versus placebo. Preclinical evidence includes mitophagy induction, lifespan extension in C. elegans and muscle-function effects in rodents.